MEDP vs SYK
Medpace vs Stryker Corporation — AI-powered side-by-side comparison
VS
SYK
Stryker Corporation
59
Buy
| Metric | MEDP | SYK |
|---|
| AI Score |
67
|
59
|
| Price |
$618.29
|
$329.92
|
| P/E Ratio |
35.31×
|
33.98×
|
| ROE |
98.3%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
65.2%
|
| Debt / Equity |
0.28×
|
0.62×
|
| Dividend Yield |
0.0%
|
1.1%
|
| RSI (14) |
62.5
|
44.6
|
| Beta |
1.151
|
0.771
|
| Expected Upside |
+1.5%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for MEDP versus SYK.
MEDP leads by 8 points.
MEDP scores 67/100 (Buy) versus SYK at 59/100 (Buy).
MEDP Committee View
83% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- Current ratio of 0.74 is tight -- limited short-term liquidity cushion — Risk
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical